Enlivex Therapeutics Ltd. ENLV
$ 1.25
5.81%
Annual report 2023
added 12-21-2024
Enlivex Therapeutics Ltd. Financial Ratios 2011-2024 | ENLV
Annual Financial Ratios Enlivex Therapeutics Ltd.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.0 | -1.5 | -7.7 | -10.4 | -7.7 | -5.1 | -25.0 | -1.0 | -3.4 | -14.2 | - | - | - |
P/S |
- | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-1.6 | -1.7 | -0.8 | -0.9 | -1.1 | -1.4 | -0.9 | -1.0 | 1.1 | -0.6 | -0.1 | -0.0 | - |
EV (Enterprise Value) |
- | - | 122 M | 122 M | 74.9 M | 22.7 M | 59.1 M | 9.74 M | 54.4 M | 91.6 M | -139 K | -65 K | - |
EBITDA per Share |
- | - | -1.05 | -0.65 | -0.97 | -1.48 | -0.61 | -39.6 | -43.5 | -23.1 | - | - | - |
EV/EBITDA |
- | -1.0 | -0.6 | 1.2 | -0.9 | -1.0 | -2.9 | -12.6 | - | - | - | ||
PEG |
-0.23 | -1.18 | 1.62 | -0.05 | -0.04 | -0.02 | -0.21 | 0.04 | 0.03 | - | - | - | |
P/B |
0.9 | 0.8 | 1.3 | 3.5 | 6.4 | 2.2 | 17.3 | 1.6 | 2.9 | 3.3 | - | - | - |
P/CF |
-1.2 | -1.9 | -6.4 | -11.2 | -10.3 | -6.9 | -27.2 | -1.1 | -3.9 | -22.3 | - | - | - |
ROE % |
-96.62 | -54.64 | -17.01 | -33.32 | -83.18 | -43.70 | -29.48 | -570.18 | -85.68 | -22.89 | - | - | - |
ROA % |
-78.92 | -45.92 | -15.21 | -29.30 | -53.44 | -38.44 | -69.13 | -150.72 | -74.89 | -21.31 | - | - | - |
ROCE % |
-95.53 | -42.27 | -21.33 | -27.19 | -74.43 | -53.50 | -25.56 | -564.63 | -85.97 | -23.08 | - | - | - |
Current Ratio |
5.5 | 6.3 | 9.4 | 8.3 | 2.8 | 8.3 | - | - | 8.1 | 14.4 | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | 192.9 | 106.5 | 18.4 | 368.5 | 1033.4 | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | -192.9 | -106.5 | -18.4 | -368.5 | -1033.3 | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Enlivex Therapeutics Ltd.
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | -0.17 | - | - | - | -0.23 | - | - | - | -0.14 | - | - | - | - | - | - | - | - | - | -0.19 | -0.28 | -0.22 | -0.32 | -0.34 | -0.25 | -0.26 | -0.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | -0.2 | - | - | - | -0.16 | - | - | - | -0.12 | - | - | - | - | - | - | - | - | - | -0.94 | - | - | - | -0.34 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
- | - | -3.45 | -6.89 | -6.89 | -3.45 | -13.52 | -20.14 | -20.14 | -10.07 | -10.07 | - | - | - | - | - | - | - | - | - | -109.36 | -218.72 | -218.72 | -109.36 | -136.29 | -53.86 | -53.86 | -26.93 | -26.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
- | - | -3.27 | -6.53 | -6.53 | -3.27 | -11.85 | -17.16 | -17.16 | -8.58 | -8.58 | - | - | - | - | - | - | - | - | - | -28.91 | -57.82 | -57.82 | -28.91 | -52.45 | -47.08 | -47.08 | -23.54 | -23.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | - | -4.20 | -8.41 | -8.41 | -4.20 | -11.54 | -14.68 | -14.68 | -7.34 | -7.34 | - | - | - | - | - | - | - | - | - | -109.40 | -218.79 | -218.79 | -109.40 | -136.35 | -53.90 | -53.90 | -26.95 | -26.95 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | 9.4 | - | 19.1 | - | 8.3 | - | 6.8 | - | 2.8 | - | - | - | 8.3 | - | - | - | 3.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency